Javascript must be enabled to continue!
Clinical signs and symptoms of toxic serum digoxin levels in neonates
View through CrossRef
Digoxin is widely used in the treatment of congestive heart failure and some arrhythmias. Digoxin toxicity may occur easily because digoxin has a narrow therapeutic index. This retrospective study was conducted to evaluate the clinical signs and symptoms of toxic serum digoxin levels in neonates. Medical reports of the neonates who had serum digoxin concentrations > 2 nanogram/milliliter (ng/ml) were reviewed in terms of patient demographics, serum digoxin concentrations, signs and symptoms of digoxin toxicity, serum digoxin and electrolyte levels, renal function tests, electrocardiograms, echocardiography, and treatments applied. Digoxin toxic levels were identified in the 13 neonates. Of the 13 neonates with digoxin toxic level, 9 (69%) were term and 8 (62%) were female. Twenty-three percent (3/13) of newborn infants were symptomatic. Symptomatic patients had statistically significantly higher serum digoxin levels, at 7.76±2.76 (5.4-10.8) ng/ml, than asymptomatic patients, at 3.31±1.09 (2.02-4.95) (p=0.036). Symptoms related to toxic digoxin levels were observed in the three neonates with plasma digoxin levels > 5 ng/ml. Gastrointestinal and central nervous system symptoms were the major clinic findings. Despite high digoxin levels, no digoxin-related arrhythmia was observed on electrocardiography, other than sinus bradycardia. Two premature neonates were treated with digoxin-specific antibody Fab fragments (DigiFab®) and hypokalemia developed in both of them. Our data suggests that symptoms related with digoxin toxic levels were observed in neonates with plasma digoxin levels > 5 ng/ml. Serum digoxin levels should be measured in case of signs and symptoms of digoxin toxicity or risk factors for such toxicity.
Hacettepe University Institute of Child Health
Title: Clinical signs and symptoms of toxic serum digoxin levels in neonates
Description:
Digoxin is widely used in the treatment of congestive heart failure and some arrhythmias.
Digoxin toxicity may occur easily because digoxin has a narrow therapeutic index.
This retrospective study was conducted to evaluate the clinical signs and symptoms of toxic serum digoxin levels in neonates.
Medical reports of the neonates who had serum digoxin concentrations > 2 nanogram/milliliter (ng/ml) were reviewed in terms of patient demographics, serum digoxin concentrations, signs and symptoms of digoxin toxicity, serum digoxin and electrolyte levels, renal function tests, electrocardiograms, echocardiography, and treatments applied.
Digoxin toxic levels were identified in the 13 neonates.
Of the 13 neonates with digoxin toxic level, 9 (69%) were term and 8 (62%) were female.
Twenty-three percent (3/13) of newborn infants were symptomatic.
Symptomatic patients had statistically significantly higher serum digoxin levels, at 7.
76±2.
76 (5.
4-10.
8) ng/ml, than asymptomatic patients, at 3.
31±1.
09 (2.
02-4.
95) (p=0.
036).
Symptoms related to toxic digoxin levels were observed in the three neonates with plasma digoxin levels > 5 ng/ml.
Gastrointestinal and central nervous system symptoms were the major clinic findings.
Despite high digoxin levels, no digoxin-related arrhythmia was observed on electrocardiography, other than sinus bradycardia.
Two premature neonates were treated with digoxin-specific antibody Fab fragments (DigiFab®) and hypokalemia developed in both of them.
Our data suggests that symptoms related with digoxin toxic levels were observed in neonates with plasma digoxin levels > 5 ng/ml.
Serum digoxin levels should be measured in case of signs and symptoms of digoxin toxicity or risk factors for such toxicity.
Related Results
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody
Ten Years of Experience in Treating Patients With Digoxin Toxicity Without Using Digoxin Fab Antibody
Background: Digoxin is extensively prescribed for cardiac diseases, so its chronic or acute toxicity commonly occur. Although digoxin specific antibodies (anti-digoxin Fab) are rec...
Radioimmunoassay of Digoxin—Interference by Digitoxin
Radioimmunoassay of Digoxin—Interference by Digitoxin
Abstract
Digitoxin interference with radioimmunoassay of digoxin may present a problem in determining digoxin concentrations in the serum of patients treated with di...
Plasma digoxin levels and ejection fraction in pediatric heart failure
Plasma digoxin levels and ejection fraction in pediatric heart failure
Background Digoxin has long been prescribed in children with heartfailure, but its efficacy has not been evaluated. A previous study atthe Department of Child Health, Dr. Cipto Man...
Association of Digoxin Use at Norwood Discharge with Fontan Completion: A Study from the Pediatric Heart Network Public Dataset
Association of Digoxin Use at Norwood Discharge with Fontan Completion: A Study from the Pediatric Heart Network Public Dataset
Abstract
Background
Digoxin use after the Norwood procedure has been associated with improved interstage survival in hypoplasti...
Surveillance of Digoxin Concentrations in Critically Ill Individuals with Heart Failure
Surveillance of Digoxin Concentrations in Critically Ill Individuals with Heart Failure
Background and Objectives: Digoxin is a pharmacological agent of natural origin that is still occasionally administered in the intensive care unit (ICU). The objective of this stud...
“CORRELATION OF PROCALCITONIN WITH SEPSIS SCREEN AND BLOOD CULTURE IN NEONATAL SEPSIS”
“CORRELATION OF PROCALCITONIN WITH SEPSIS SCREEN AND BLOOD CULTURE IN NEONATAL SEPSIS”
BACKGROUND – Sepsis in neonates may be difcult to differentiate from other conditions, because the clinical signs are non-specic. It is a
common cause of morbidity and mortality ...
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
ASSOCIATION OF THE SERUM LEVELS OF C-REACTIVE PROTEIN WITH ITS GENE POLYMORPHISMS AND ACUTE CORONARY SYNDROME
Objectives
To investigate the association of the serum levels of CRP with its gene polymorphisms and the risk of ACS in Chinese Han population in Sunan region.
...

